Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features
Conditions
Interventions
Intervention1: Anti depressant medication: Clinician decided anti depressant medication will be provided. Investigator will not change or suggest any medication.
Sponsors
AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria – MDD group 1. Age 18 to 55 years 2. Any gender 3. Right-handed subjects 4. Willing to give written informed consent 5. Ability to read Hindi or English language 6. Meeting DSM 5 criteria for Major Depressive Disorder (MDD) 7. Treatment naïve or Treatment free from prior 2 weeks or on a stable standard antidepressant regimen with no change in treatment in previous 4-weeks. 8. Prescribed antidepressants for treatment of MDD on the day of screening/recruitment 9. HAMD score = 17 (moderate to severe depression) (Zimmerman et al., 2013) Inclusion criteria – Healthy controls 1. Age (18 to 55 years) matched (± 5 years) and Gender matched 2. Right-handed 3. Willing to give written informed consent 4. Ability to read Hindi or English language 5. Not suffering from any psychiatric illness (on clinical evaluation)
Exclusion criteria
Exclusion criteria: 1. Suffering from any psychotic symptoms or other psychiatric disorder or substance use disorder (except caffeine & nicotine) through clinical interview using DSM 5 2. Persistent Depressive Disorder (dysthymia), Premenstrual Dysphoric Disorder, Depressive Disorder Due to Another Medical Condition, Substance/ Medication Induced Depressive Disorder, Other and Unspecified Depressive Disorders based on DSM 5 3. History of seizures 4. Pregnancy/ Lactation 5. Uncontrolled medical illness 6. History suggestive of space occupying brain lesion or cerebrovascular accident 7. Current prescription or history within last 3-months of receiving any Psychotherapy/Neuromodulation 8. Actively suicidal as defined by a score of 4 on item 3 of HAMD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HAMD scores & cortical activity within patient group & comparison of cortical activity between patient group & healthy groupTimepoint: at baseline & after 4 & 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| BDNF gene polymorphism correlation with depression severityTimepoint: baseline | — |
Countries
India
Contacts
Public ContactRohit Verma
All India Institute of Medical Sciences New Delhi
Outcome results
None listed